CRDL.TO

Cardiol Therapeutics Inc. [CRDL.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CRDL.TO Stock Summary

In the News

CRDL.TO Financial details

Company Rating
-
Market Cap
166.04M
Income
-27.28M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
17 May 2024
P/E
-3.62
Forward P/E
-
PEG
-0.26
P/S
-
P/B
2.55
P/C
-
P/FCF
-3.24
Quick Ratio
5.08
Current Ratio
5.29
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.43
EPS next Y
-
EPS next Q
-
EPS this Y
144.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
30.43%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-57%
ROE
-57%
ROC
-0.9%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.68-2.94
52W High
-
52W Low
-
RSI
54
Rel Volume
0.74
Avg Volume
153.59K
Volume
113.49K
Perf Week
0.35%
Perf Month
1.77%
Perf Quarter
-8.01%
Perf Half Y
-15.09%
-
-
-
-
Beta
0.711
-
-
Volatility
0.02%, 0.05%
Prev Close
1.77%
Price
1.435
Change
2.5%

Something similar

Top by Market Cap
BRH.DE
V
LLY.SW
1YD.DE
MSF.DE
Same Sector
NKTR
INM
002898.SZ
KREBSBIO.NS
TOL.ST
Same Price Range
1527.HK
3680.HK
M44U.SI
6118.HK
AIKO
Similar Market Cap
LYS4.DE
0510.HK
CHRS
FLL
FRI

Company Profile

Healthcare Drug Manufacturers - Specialty & Generic
  • Volume Average 153.59K
  • Market Capitalization 166.04M
  • Employee 22
  • CEO Mr. David G. Elsley MBA
  • Headquarters Oakville,ON,CA
  • IPO Date 2018-12-20
  • Website https://www.cardiolrx.com

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.